Jane Street Group LLC Decreases Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Jane Street Group LLC cut its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 5.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 93,876 shares of the company’s stock after selling 5,160 shares during the period. Jane Street Group LLC owned 0.18% of TScan Therapeutics worth $468,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Great Point Partners LLC boosted its holdings in TScan Therapeutics by 8.0% in the 3rd quarter. Great Point Partners LLC now owns 1,016,375 shares of the company’s stock worth $5,062,000 after buying an additional 75,544 shares during the period. Checkpoint Capital L.P. bought a new position in TScan Therapeutics in the 3rd quarter worth approximately $4,110,000. State Street Corp boosted its holdings in TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock worth $3,767,000 after buying an additional 148,414 shares during the period. abrdn plc boosted its holdings in TScan Therapeutics by 27.2% in the 3rd quarter. abrdn plc now owns 371,655 shares of the company’s stock worth $1,851,000 after buying an additional 79,511 shares during the period. Finally, Marshall Wace LLP boosted its holdings in TScan Therapeutics by 60.8% in the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after buying an additional 116,316 shares during the period. 82.83% of the stock is owned by institutional investors.

TScan Therapeutics Stock Down 2.9 %

Shares of NASDAQ:TCRX opened at $2.98 on Tuesday. The firm has a fifty day moving average price of $4.08 and a two-hundred day moving average price of $5.25. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics, Inc. has a one year low of $2.60 and a one year high of $9.69. The company has a market cap of $159.05 million, a price-to-earnings ratio of -2.81 and a beta of 0.91.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.86 million. Analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a report on Monday, December 23rd. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a report on Wednesday, December 11th.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.